Page 39
(
...Continued from page 38) market access; incentivising innovation; supporting skills development; and boosting collaboration across industry, academia and the NHS.
Initiatives such as these should help to ensure that many more UK life sciences companies and scientists follow in the footsteps of Professor Edwards and take their place on the global stage.
COOLING TREATMENT
An innovative scalp cooling system developed by Huddersfield-based Paxman Coolers Ltd is being introduced into French hospitals and cancer treatment centres, thanks to support from UK Trade & Investment.
The system, which helps to reduce or even prevent hair loss in chemotherapy patients, was first sold to hospitals in the UK in 1997. Since then it has become an international success, with sales in countries such as Sweden, the Netherlands, Switzerland, Finland, Denmark and Greece. In 2009, Paxman Coolers approached UK Trade & Investment for help in exploring the French market, commissioning an Overseas Market Introduction Service (OMIS) report. This led to sales to a Paris hospital and numerous enquiries.
Operations director Richard Paxman said: “We are really pleased with the progress we are making in the French market. The help we have had from UK Trade & Investment has undoubtedly been crucial to our success.”
www.paxman-coolers.co.uk
CLUSTER GROWTH
The government has launched a Therapeutic Capability Clusters programme to stimulate collaboration between industry, government and academia to increase the translation of ideas into new medicines and therapies. Dr Richard Barker, director general of the Association of the British Pharmaceutical Industry (ABPI), said: “This initiative will create true comparative advantage for the UK in translational medicine. The programme capitalises on our vibrant and economically important life sciences sector, to attract increased inward investment from the global pharmaceutical industry.”
CENTRE OF EXCELLENCE
Irish company ICON, a global service provider to the pharmaceutical, biotechnology and medical device industries, recently signed a collaborative agreement with the Central Manchester University Hospitals NHS Foundation Trust (CMFT) to develop a purpose-built medicine facility.
Dr Thomas Frey, president, ICON Development Solutions, said: “We are delighted to be collaborating with CMFT and the Manchester Academic Health Centre to continue to develop the region as an international centre of excellence in translational medicine. Moving to a hospital-based setting also meets the needs of our customers, who are increasingly looking to run their first in-human studies in hospital environments.”
Mike Deegan, chief executive of CMFT, commented: “Our aim is to build upon our investments in facilities and high-calibre clinical academic staff to consolidate our reputation as a leading international research hospital. This exciting new collaboration with ICON is a major step for the trust and will accelerate the translation of research discoveries into new medicines.”
www.iconclinical.com
NEW ANTIBODIES HUB
In 2009, US firm Novus Biologicals, a supplier of antibodies and related products, established its new European distribution hub in Cambridge.
CFO Todd Padgett said: “We looked at a lot of possible locations in Europe for this new office, but Cambridge was the equal, or superior, to all in terms of science base. We particularly like the cluster of science and research parks in the Cambridge area. These could provide the basis for further growth for Novus as we move forward.”
www.novusbio.com
For more information, visit
www.ukti.gov.uk/export/sectors/lifesciences.html or contact Jane Grady on 020 7215 8393 or email
jane.grady@
ukti.gsi.gov.uk
springboard: |
www.ukti.gov.uk | page 39
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52